Selecta Biosciences (SELB) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS
Selecta Biosciences (NASDAQ:SELB) announced its quarterly earnings data on Friday. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.10, MarketWatch Earnings reports. The firm had revenue of $0.90 million for the quarter.
Shares of SELB stock opened at $2.17 on Friday. The firm has a market capitalization of $48.76 million, a P/E ratio of -0.68 and a beta of 1.55. Selecta Biosciences has a one year low of $1.41 and a one year high of $16.55.
In other Selecta Biosciences news, Director Amir Nashat acquired 1,166,666 shares of Selecta Biosciences stock in a transaction on Friday, January 25th. The shares were bought at an average price of $1.50 per share, with a total value of $1,749,999.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 25.20% of the stock is currently owned by insiders.
Several analysts have recently weighed in on the company. Stifel Nicolaus reissued a “buy” rating and set a $7.00 price objective on shares of Selecta Biosciences in a report on Friday. Mizuho decreased their price objective on Selecta Biosciences to $4.00 and set a “buy” rating on the stock in a report on Monday, February 4th. Needham & Company LLC decreased their price target on Selecta Biosciences to $12.00 and set a “buy” rating on the stock in a research note on Monday, January 28th. ValuEngine lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. Selecta Biosciences currently has an average rating of “Hold” and a consensus price target of $15.46.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/selecta-biosciences-selb-releases-quarterly-earnings-results-beats-expectations-by-0-10-eps/2897075.html.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
See Also: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.